Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medi
Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $3.04 b...
Since November 2025, Quest has been in a holding pattern, posting a small return of 2.6% while floating around $194.06. The stock also fell short of the S&P ...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
It’s time to crown a winner: defending champion Emily Flippen faces off against Cinderella challenger Loren Horst in the Market Cap Madness World Championship.
Quest Diagnostics delivered first quarter results that exceeded Wall Street’s revenue and profit expectations, driven by broad-based demand for its clinical ...
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 9.2% year on ...
